autologous dendritic cell vaccine (Duke University)

This autologous dendritic cell vaccine, developed by Duke University, is an investigational cellular immunotherapy designed for the treatment of metastatic melanoma. The therapeutic process involves collecting a patient's own peripheral blood mononuclear cells via leukapheresis, which are then differentiated into dendritic cells ex vivo. These dendritic cells are pulsed with specific melanoma-associated antigens, typically gp100 and tyrosinase peptides, or sometimes autologous tumor lysate, to program them to recognize the patient's cancer cells. After maturation, the antigen-loaded dendritic cells are re-infused into the patient, where they act as professional antigen-presenting cells to activate and expand tumor-specific T-cell populations. This approach is intended to stimulate a targeted immune response against melanoma cells and is often evaluated in conjunction with systemic cytokines like interleukin-2 (aldesleukin) to further boost T-cell activity.

Other names

antigen-pulsed autologous dendritic cellsDuke University melanoma DC vaccinegp100 and tyrosinase-pulsed dendritic cell vaccinegp-100 and tyrosinase-pulsed dendritic cell vaccinegp 100 and tyrosinase-pulsed dendritic cell vaccine